Agilent introduces 3X faster scan cycle spectrometer
spectrometer (MS) that allows the identification of 60-80 per cent
more peptides than preceding models in proteomic applications. The
spectrometer will lead to a better understanding of diseases like
cancer and assisting drug discovery efforts.
The LC/MSD Trap XCT Ultra is the latest system of Agilent's integrated approach to facilitating proteomics research. Its features make it suitable for metabolite characterisation, natural products screening, product degradation studies and food and environmental analysis, which require excellent sensitivity and fast scanning capability.
The Agilent 1100 Series LC/MSD Trap XCT Ultra claims to offer improved scan cycle times, enabling collection of mass spectra at rates up to three times faster than its predecessors.
"The high resolution, scan speed and sensitivity of the LC/MSD Trap XCT Ultra make it a powerful tool for a wide range of qualitative applications in which high performance and productivity are essential, particularly in proteomics research," said Ken Imatani, product marketing manager for Agilent.
The system, which is based on an advanced multipole ion trap technology, has a full-scan MS/MS sensitivity specification of 250 femtograms for reserpine. The system also has two new data-dependent neutral-loss analysis modes that provides improved data quality for analysis of phosphopeptides and glycopeptides.
The Agilent 1100 Series LC/MSD Trap XCT Ultra ion trap mass spectrometer (G4533AA) includes mass spectrometer, electrospray ionisation source, data system and LC/MSD Trap software (6.0). It is expected to ship in July 2005.
